{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:55:44Z","timestamp":1792760144099,"version":"4.5.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>RAD51C<\/jats:italic> and RAD51D<\/jats:italic> are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C\/D<\/jats:italic> could guide therapeutic decision-making and improve survival.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize the clinical and tumor characteristics of germline RAD51C\/D<\/jats:italic> PV carriers, including the evaluation of HRD status.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included 91 index patients plus 90 relatives carrying germline RAD51C\/D<\/jats:italic> PV (n\u2009=\u2009181) in Spanish hospitals from January 1, 2014, to December 31, 2021. Genomic and functional HRD biomarkers were assessed in untreated breast and ovarian tumor samples (n\u2009=\u200945) from June 2022 to February 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Clinical and pathologic characteristics were assessed using descriptive statistics. Genomic HRD by genomic instability scores, functional HRD by RAD51, and gene-specific loss of heterozygosity were analyzed. Associations between HRD status and tumor subtype, age at diagnosis, and gene-specific loss of heterozygosity in RAD51C\/D<\/jats:italic> were investigated using logistic regression or the t<\/jats:italic> test.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 9507 index patients were reviewed, and 91 patients (1.0%) were found to carry a PV in RAD51C\/D<\/jats:italic>; 90 family members with a germline PV in RAD51C\/D<\/jats:italic> were also included. A total of 157 of carriers (86.7%) were women and 181 (55.8%) had received a diagnosis of cancer, mainly breast cancer or ovarian cancer. The most prevalent PVs were c.1026+5_1026+7del (11 of 56 [19.6%]) and c.709C&amp;gt;T (9 of 56 [16.1%]) in RAD51C<\/jats:italic> and c.694C&amp;gt;T (20 of 35 [57.1%]) in RAD51D<\/jats:italic>. In untreated breast cancer and ovarian cancer, the prevalence of functional and genomic HRD was 55.2% (16 of 29) and 61.1% (11 of 18) for RAD51C<\/jats:italic>, respectively, and 66.7% (6 of 9) and 90.0% (9 of 10) for RAD51D<\/jats:italic>. The concordance between HRD biomarkers was 91%. Tumors with the same PV displayed contrasting HRD status, and age at diagnosis did not correlate with the occurrence of HRD. All breast cancers retaining the wild-type allele were estrogen receptor positive and lacked HRD.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of germline RAD51C\/D<\/jats:italic> breast cancer and ovarian cancer, less than 70% of tumors displayed functional HRD, and half of those that did not display HRD were explained by retention of the wild-type allele, which was more frequent among estrogen receptor\u2013positive breast cancers. Understanding which tumors are associated with RAD51C\/D<\/jats:italic> and HRD is key to identify patients who can benefit from targeted therapies, such as PARP (poly [adenosine diphosphate\u2013ribose] polymerase) inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.7811","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T15:32:12Z","timestamp":1713799932000},"page":"e247811","source":"Crossref","is-referenced-by-count":26,"title":["Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C\/D<\/i> Breast or Ovarian Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Sara","family":"Torres-Esquius","sequence":"first","affiliation":[{"name":"Hereditary Cancer Genetics Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Llop-Guevara","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"Translational Medicine, DNA Damage Response Department, AstraZeneca, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Guti\u00e9rrez-Enr\u00edquez","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Genetics Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Romey","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Universit\u00e4tsklinikum Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0lex","family":"Teul\u00e9","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Llort","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitari Parc Taul\u00ed, Sabadell, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Herrero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Miguel Servet de Zaragoza, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1nchez-Henarejos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clinical University Hospital Virgen Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vallmaj\u00f3","sequence":"additional","affiliation":[{"name":"Genetic Counseling Unit, Arnau de Vilanova University Hospital, Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Gonz\u00e1lez-Santiago","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Chirivella","sequence":"additional","affiliation":[{"name":"Cancer Genetic Counseling, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana Maria","family":"Cano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Gra\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Xerencia de Xesti\u00f3n Integrada de A Coru\u00f1a, Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Molecular Oncology Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"D\u00edaz de Corcuera","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario de Galdakao, Galdakao-Usansolo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Ramon y Cajal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Sanz","sequence":"additional","affiliation":[{"name":"Unidad de C\u00e1ncer Familiar y Hereditario, Althaia Xarxa Assistencial Universit\u00e0ria de Manresa, Manresa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology of Southern Catalonia (IOCS), Hospital Universitari Sant Joan de Reus, Reus, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Otero","sequence":"additional","affiliation":[{"name":"Institute of Oncology and Molecular Medicine of Asturias (IMOMA) S. A., Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Churruca","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Donostia, San Sebasti\u00e1n, Gipuzkoa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"S\u00e1nchez-Heras","sequence":"additional","affiliation":[{"name":"Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Servitja","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Guill\u00e9n-Ponce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal (IRYCIS), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Brunet","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Program, Catalan Institute of Oncology, Girona, Spain"},{"name":"Precision Oncology Group (OncoGIR-Pro), Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona (IDIBGI), Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Universit\u00e4tsklinikum Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Serra","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[{"name":"Hereditary Cancer Genetics Group, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"},{"name":"Medical Oncology Department, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"5","key":"zoi240290r1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes\u2014association analysis in more than 113,000 women.","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240290r2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer.","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240290r3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.","volume":"112","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"zoi240290r4","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240290r5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing.","volume":"110","author":"Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi240290r6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.","volume":"33","author":"Couch","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi240290r7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer.","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7970","key":"zoi240290r8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-023-06179-1","article-title":"Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.","volume":"619","author":"Greenhough","year":"2023","journal-title":"Nature"},{"issue":"1","key":"zoi240290r9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.","volume":"13","author":"Suszynska","year":"2020","journal-title":"J Ovarian Res"},{"issue":"1","key":"zoi240290r10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-014-3078-4","article-title":"RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.","volume":"147","author":"Blanco","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"zoi240290r11","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/ijc.v134.9","article-title":"About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.","volume":"134","author":"Guti\u00e9rrez-Enr\u00edquez","year":"2014","journal-title":"Int J Cancer"},{"issue":"12","key":"zoi240290r12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi240290r13","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi240290r14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"8","key":"zoi240290r15","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","article-title":"Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification.","volume":"82","author":"Pellegrino","year":"2022","journal-title":"Cancer Res"},{"issue":"11","key":"zoi240290r16","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial.","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"zoi240290r17","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.annonc.2021.09.003","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.","volume":"32","author":"Llop-Guevara","year":"2021","journal-title":"Ann Oncol"},{"key":"zoi240290r18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ygyno.2023.01.026","article-title":"A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.","volume":"171","author":"Blanc-Durand","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"13","key":"zoi240290r19","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-22-3335","article-title":"RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.","volume":"29","author":"Compadre","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"16","key":"zoi240290r20","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-22-3156","article-title":"Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.","volume":"29","author":"Pikkusaari","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi240290r21","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency.","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"zoi240290r22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1093\/jnci\/djz045","article-title":"Combined tumor sequencing and case-control analyses of RAD51C in breast cancer.","volume":"111","author":"Li","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"zoi240290r23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"zoi240290r24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"zoi240290r25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.963728","article-title":"Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: a case report.","volume":"12","author":"Gomez-Puerto","year":"2022","journal-title":"Front Oncol"},{"key":"zoi240290r26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00258","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial.","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"zoi240290r27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.","volume":"167","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"10","key":"zoi240290r28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/jpm12101595","article-title":"Alterations in homologous recombination-related genes and distinct platinum response in metastatic triple-negative breast cancers: a subgroup analysis of the ProfiLER-01 trial.","volume":"12","author":"Bonnet","year":"2022","journal-title":"J Pers Med"},{"issue":"5","key":"zoi240290r29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"12","key":"zoi240290r30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jmoldx.2022.09.004","article-title":"Homologous recombination deficiency as an ovarian cancer biomarker in a real-world cohort: validation of decentralized genomic profiling.","volume":"24","author":"Denkert","year":"2022","journal-title":"J Mol Diagn"},{"issue":"6","key":"zoi240290r31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"12","key":"zoi240290r32","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane\u2013based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"zoi240290r33","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer.","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"zoi240290r34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/humu.v43.3","article-title":"A decade of RAD51C and RAD51D germline variants in cancer.","volume":"43","author":"Boni","year":"2022","journal-title":"Hum Mutat"},{"issue":"9","key":"zoi240290r35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"key":"zoi240290r36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ygyno.2023.11.019","article-title":"Pathogenic germline variants in non-BRCA1\/2 homologous recombination genes in ovarian cancer: analysis of tumor phenotype and survival.","volume":"180","author":"Kahn","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"11","key":"zoi240290r37","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","article-title":"The context-specific role of germline pathogenicity in tumorigenesis.","volume":"53","author":"Srinivasan","year":"2021","journal-title":"Nat Genet"},{"issue":"1","key":"zoi240290r38","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat Commun"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2817854\/torresesquius_2024_oi_240290_1713196752.45293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T15:32:15Z","timestamp":1713799935000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2817854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7811","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]}}}